194 related articles for article (PubMed ID: 18578560)
1. Tipranavir: a review of its use in the management of HIV infection.
Orman JS; Perry CM
Drugs; 2008; 68(10):1435-63. PubMed ID: 18578560
[TBL] [Abstract][Full Text] [Related]
2. Tipranavir: PNU 140690, tipranivir.
Drugs R D; 2006; 7(1):55-62. PubMed ID: 16620137
[TBL] [Abstract][Full Text] [Related]
3. Tipranavir: a novel nonpeptidic protease inhibitor of HIV.
King JR; Acosta EP
Clin Pharmacokinet; 2006; 45(7):665-82. PubMed ID: 16802849
[TBL] [Abstract][Full Text] [Related]
4. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
Hicks CB; Cahn P; Cooper DA; Walmsley SL; Katlama C; Clotet B; Lazzarin A; Johnson MA; Neubacher D; Mayers D; Valdez H;
Lancet; 2006 Aug; 368(9534):466-75. PubMed ID: 16890833
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients.
Goebel FD; MacGregor TR; Sabo JP; Castles M; Johnson PA; Legg D; McCallister S
HIV Clin Trials; 2010; 11(1):28-38. PubMed ID: 20400409
[TBL] [Abstract][Full Text] [Related]
6. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.
Luna B; Townsend MU
Clin Ther; 2007 Nov; 29(11):2309-18. PubMed ID: 18158073
[TBL] [Abstract][Full Text] [Related]
7. Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients.
de Mendoza C; Morelló J; Garcia-Gascó P; Rodríguez-Novoa S; Soriano V
Expert Opin Pharmacother; 2007 Apr; 8(6):839-50. PubMed ID: 17425479
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ritonavir dose reduction based on the tipranavir inhibitory quotient in HIV-infected patients on salvage antiretroviral therapy with tipranavir/ritonavir.
Moltó J; Valle M; Santos JR; Miranda C; Cedeño S; Negredo E; Yritia M; Videla S; Clotet B
AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1191-6. PubMed ID: 20860529
[TBL] [Abstract][Full Text] [Related]
9. Tipranavir: a ritonavir-boosted protease inhibitor.
Croom KF; Keam SJ
Drugs; 2005; 65(12):1669-77; discussion 1678-9. PubMed ID: 16060700
[TBL] [Abstract][Full Text] [Related]
10. Tipranavir: new drug. HIV protease inhibitor. A last resort.
Prescrire Int; 2006 Dec; 15(86):217-9. PubMed ID: 17167925
[TBL] [Abstract][Full Text] [Related]
11. Drug interactions of tipranavir, a new HIV protease inhibitor.
Morello J; Rodriguez-Novoa S; Jimenez-Nacher I; Soriano V
Drug Metab Lett; 2007 Jan; 1(1):81-4. PubMed ID: 19356024
[TBL] [Abstract][Full Text] [Related]
12. Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
Cooper DA; Cordery DV; Zajdenverg R; Ruxrungtham K; Arastéh K; Bergmann F; Neto JL; Scherer J; Chaves RL; Robinson P;
PLoS One; 2016; 11(1):e0144917. PubMed ID: 26730818
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents.
Salazar JC; Cahn P; Yogev R; Negra MD; Castelli-Gattinara G; Fortuny C; Flynn PM; Giaquinto C; Ruan PK; Smith ME; Mikl J; Jelaska A;
AIDS; 2008 Sep; 22(14):1789-98. PubMed ID: 18753862
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51).
Walmsley SL; Katlama C; Lazzarin A; Arestéh K; Pierone G; Blick G; Johnson M; Meier U; MacGregor TR; Leith JG
J Acquir Immune Defic Syndr; 2008 Apr; 47(4):429-40. PubMed ID: 18176328
[TBL] [Abstract][Full Text] [Related]
15. Tipranavir: a new option for the treatment of drug-resistant HIV infection.
Temesgen Z; Feinberg J
Clin Infect Dis; 2007 Sep; 45(6):761-9. PubMed ID: 17712762
[TBL] [Abstract][Full Text] [Related]
16. Tipranavir.
Plosker GL; Figgitt DP
Drugs; 2003; 63(15):1611-8. PubMed ID: 12887268
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients.
Gathe JC; Pierone G; Piliero P; Arasteh K; Rubio R; Lalonde RG; Cooper D; Lazzarin A; Kohlbrenner VM; Dohnanyi C; Sabo J; Mayers D
AIDS Res Hum Retroviruses; 2007 Feb; 23(2):216-23. PubMed ID: 17263650
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study.
Markowitz M; Slater LN; Schwartz R; Kazanjian PH; Hathaway B; Wheeler D; Goldman M; Neubacher D; Mayers D; Valdez H; McCallister S
J Acquir Immune Defic Syndr; 2007 Aug; 45(4):401-10. PubMed ID: 17554217
[TBL] [Abstract][Full Text] [Related]
19. Low trough levels of tipranavir in a combination antiretroviral therapy of tipranavir/ritonavir and tenofovir require therapeutic drug monitoring.
Langmann P; Winzer R; Schirmer D; Heinz W; Leyh M; Guhl C; Weissbrich B; Klinker H
Eur J Med Res; 2008 Oct; 13(10):469-71. PubMed ID: 19008174
[TBL] [Abstract][Full Text] [Related]
20. Tipranavir: a protease inhibitor for HIV salvage therapy.
Dong BJ; Cocohoba JM
Ann Pharmacother; 2006; 40(7-8):1311-21. PubMed ID: 16788094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]